Arovella Therapeutics (ASX:ALA) FCF Margin % : -1,597.79% (As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Arovella Therapeutics's Free Cash Flow for the six months ended in Dec. 2024 was A$-2.17 Mil. Arovella Therapeutics's Revenue for the six months ended in Dec. 2024 was A$0.14 Mil. Therefore, Arovella Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was -1,597.79%.

As of today, Arovella Therapeutics's current FCF Yield % is -5.82%.

The historical rank and industry rank for Arovella Therapeutics's FCF Margin % or its related term are showing as below:

ASX:ALA' s FCF Margin % Range Over the Past 10 Years
Min: -41429.41 Med: -712.58 Max: -30.03
Current: -4511.72

During the past 13 years, the highest FCF Margin % of Arovella Therapeutics was -30.03%. The lowest was -41429.41%. And the median was -712.58%.

ASX:ALA's FCF Margin % is ranked worse than
88.9% of 1000 companies
in the Biotechnology industry
Industry Median: -121.695 vs ASX:ALA: -4511.72

Arovella Therapeutics FCF Margin % Historical Data

The historical data trend for Arovella Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics FCF Margin % Chart

Arovella Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

-613.88

-1,579.77

-2,308.78

-1,576.60

-41,429.41

Arovella Therapeutics Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-691.32	-14,500.00	-29,722.22	-48,544.44	-1,597.79

Competitive Comparison of Arovella Therapeutics's FCF Margin %

For the Biotechnology subindustry, Arovella Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arovella Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Arovella Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Arovella Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-7.043	/	0.017
	=	-41,429.41 %

Arovella Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-2.173	/	0.136
	=	-1,597.79 %

Arovella Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

E4NA:Germany

Address

84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines